Differential signature of fecal microRNAs in patients with pancreatic cancer

Abstract

Abstract. The potential value of microRNAs as new biomarkers for pancreatic cancer (PCa) screening was explored in this study. Fecal microRNAs from stool samples obtained from 29 PCa patients, 22 chronic pancreatitis (CP) patients and 13 normal individuals were extracted, and 7 microRNAs (miR-16, miR-21, miR-155, miR-181a, miR-181b, miR-196a and miR-210) were detected. miR-181b and miR-210 discriminated PCa from normal individuals with receiver operating characteristic (ROC) curves and area under curve (AUC-ROC) of 0.745 and 0.772, respectively. There was a significant correlation between miR-196a and the maximum tumor diameter (Spearman r=0.516, P=0.041). These findings suggest that fecal microRNAs such as miR-181b and miR-210 may have potential to be used as new biomarkers for PCa screening.

Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis

“…Next, we found that 21 studies were performed in Asian populations and the other 15 studies were performed in Caucasian populations. A total of 25 studies detected miRNA in blood (such as whole blood [24, 26, 28], serum [9, 20, 22, 23, 27, 29, 32, 34] and plasma samples [2, 8, 10, 11, 13, 15, 16, 18, 19, 25, 35]), and 11 studies detected miRNA in non-blood samples (including bile [13], cyst fluid [17], pancreatic juice [12, 30], salivary [7, 33], and stool [21, 31]). We evaluated 19 studies for assessing the diagnostic efficacy of multiple miRNAs [2, 13, 15, 17–22, 26–32, 34] and single miRNAs using meta-analysis for discriminating patients with PaCa from healthy controls in 17 studies [7–12, 16, 23–25, 33, 35] in these 29 articles.…”

“…In multiple miRNA assays, miR-21 [7, 11, 12, 15, 17–20, 23, 31], miR-155 [12, 13, 15, 18, 19, 31] and miR-210 [15, 18, 19, 21, 30] were used most frequently in the included studies. Moreover, we further found that the diagnostic accuracy of miRNAs to differentiate PDAC from controls (SEN:87%, SPE: 86%, AUC: 0.93) indicating a higher accuracy compared with applications on PaCa patients (SEN: 80%, SPE:83%, AUC: 0.86) (Table 2).…”

Early Diagnosis of Pancreatic Cancer: Challenges and New Developments

“…Ren et al evaluated the miRNA signature (miR-16, -21, -155, -181a, -181b, -196a and -210) in stool samples collected from PC (n = 29) and CP (n = 22) patients, and healthy controls (n = 13). Among these, miR-181b and -210 discriminated PC from normal individuals with receiver operator characteristic curves and AUCs of 0.745 and 0.772, respectively, and a significant correlation was observed between tumor diameter and miR-196a expression (Spearman’s rank: 0.516; p = 0.041) [73]. While looking for an miRNA profile for the early detection of PC, Yu et al , in a comprehensive miRNA analysis, evaluated 700 miRNAs in PanIN lesions via quantitative real-time PCR.…”

Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer

“…There were 80 studies that detected miRNAs in the blood (such as whole blood [ 14 , 46 , 53 , 54 ], serum [ 24 , 27 , 28 , 30 , 32 , 39 , 40 , 50 , 51 ], and plasma samples [ 3 , 11 – 13 , 21 , 23 , 26 , 33 , 34 , 36 – 38 , 52 ]), and 29 studies detected miRNA in nonblood samples (including tissues [ 41 – 43 , 45 , 47 – 49 , 55 ], pancreatic juice [ 44 ], and stool [ 22 , 25 , 31 , 35 ]). We included 71 studies to evaluate the diagnostic efficacy of single miRNAs [ 12 , 13 , 21 , 22 , 26 – 29 , 33 , 34 , 36 , 38 , 39 , 41 – 43 , 47 , 54 , 55 ] and multiple miRNAs [ 11 , 14 , 23 – 25 , 30 – 32 , 35 , 37 , 40 , 44 – 46 , 48 – 53 ] for distinguishing patients with PaC from controls in 38 studies. The selected studies adopted the reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry (IHC) method...…”